Recombinant Therapeutics Player

Bharat Serums and Vaccines has been focusing on developing new generation recombinant therapeutics that replace the traditional plasma products

Bharat Serums and Vaccines

Business: Manufacturing and marketing of biological products

CEO: Bharat Daftary (CMD)

Biotech Revenue: Rs 108.49 crore

Start-up Year: 1971

Address: 16th Floor, Hoechst House, Nariman Point, Mumbai - 400 021

Tel.: 91-22-56560900

Fax: 91-22-56560901

Website: www.bharatserums.com

Bharat Serums and Vaccines (BSV) has increased its biotechnology sales in 2006-07 by registering a 39 percent growth with sales crossing Rs 100 crore. The previous year it had registered a slight negative growth of 3.64 percent. However, its biotech sales revenue touched Rs 108.49 crore in 2006-07 over the last year's sales revenue of Rs 78.05 crore. The company attributes the good growth in biotech sales to the increase in the sales in the domestic market.

Official sources in the company noted that the fall in biotech sales was due to partial closure of the biotech plant during 2005-06 with an objective to expand the facility. Considering the growing market for biologicals and good margins, BSV has expanded its existing biotech facility. Hence BSV's biotech sales have increased during the last financial year. During 2004-05, BSV has registered a marginal growth of 1.66 percent over the previous year's sales of Rs 79.68 crore.

Bharat Serums and Vaccines manufactures and markets biological, pharmaceutical and biotechnology products. BSV holds a formidable market share in India for plasma derivatives and is constantly expanding its range of products by introducing new and improved therapies based on strong research and development initiatives and efforts. Its biotech products available in the market include plasma derivatives, monoclonal antibodies, hormones and in cardiovascular space.

Bharat Serums and Vaccines, a flagship company floated by Dr Vinod G Daftary and one of the fastest growing pharmaceutical firms in the country, has received a total of Rs 10.48 crore for two of its projects costing Rs 7.07 crore and Rs 3.41 crore from the Department of Science and Technology (DST) as loan for research and development work pertaining to medicines. Besides, BSV is investing about 7 percent of its total revenue in R&D infrastructure including high quality laboratory facilities, experienced research scientists and personnel. The R&D activities have been granted recognition by the Department of Scientific and Industrial Research.

Bharat Serums and Vaccines has set up a joint venture company with Cadila Healthcare to produce a NDDS for an approved anti-cancer product for the global markets. In biotechnology space, BSV's R&D team has been focusing on developing new generation recombinant therapeutics that replaces the traditional plasma products, which are in short supply worldwide due to the dependence on human donors, and runs the risk of viral infections like HIV. Its efforts on the recombinant therapeutics will overcome these shortcomings with higher safety and efficacy profiles and consistent supply. BSV is one of the few companies globally with in-house expertise to conduct genetic engineering, process development and scale-up.